IPO

The Mediterranean chain is betting on the "swicy" trend, launching a Hot Honey Harissa menu and new fries to challenge fast-casual rivals.

China's literary giant Yuewen leverages AI and a new generation of creators to build a global IP empire, from novels to AI-dramas and merchandise.

The Scottish auctioneer opens a Hong Kong hub, a strategic play to dominate the region's booming rare whisky market fueled by new policies and insatiable demand.

The logistics giant's global strategy pays off, with new regions turning a profit for the first time and Southeast Asia dominance solidifying its growth.

A new alliance between E-Power and Raytel aims to solve AI's biggest bottlenecks by combining ultra-fast optics with advanced power grids.

The InsurTech firm closed a major financing deal to accelerate its AI platform, but the move triggered a stock dip and questions about shareholder dilution.

A new energy firm will drill for oil in Greenland under a legacy permit, clashing with the nation's 2021 ban and setting up a high-stakes environmental fight.

The tech firm's massive capital raise via a unique offering aims to bolster its dual-engine model amid stock volatility and significant shareholder dilution.

RenX Enterprises touts massive growth after a reverse split, but a closer look reveals dilution risks, a heavy debt load, and a paid promotional campaign.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Neutech Group builds on its education, healthcare, and wellness strategy, but a closer look at its 2025 financials reveals a more complex picture.

The digital infrastructure firm secured new funding for expansion, but a steep discount in its offering has rattled investors and sent its share price plunging.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

The advanced optics maker announced a stock offering to fund operations as it navigates record revenue growth alongside plummeting profitability.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

An activist investor and top proxy advisor ISS are urging ProCap Financial shareholders to reject a controversial AI merger, citing conflicts and dilution.

A Florida firm says its 15-year study proves 'Hypergrowth Stocks' are a unique asset class. But can a 40% growth metric truly redefine investing?

An ambitious plan to democratize wealth for small businesses, backed by prominent investors, confronts significant SEC hurdles and legislative dependencies.

As OpenAI shelves its costly Sora video project, smaller firms like ReelTime tout a new path: efficiency over brute force. Is this the future of AI video?

A new deal with a top European insurer validates Global AI's advanced platform in a high-stakes market, but can its financials keep pace with its tech?